IDH testing under scrutiny {#s1}
==========================

Isocitrate dehydrogenase 1 (IDH1) gene mutations are found in 60 -- 90% of diffuse and anaplastic gliomas and secondary glioblastomas \[[@b1], [@b2]\]. IDH testing supports neuropathological differential diagnosis, e.g., for differentiation of oligodendrogliomas from other tumors with clear cell appearance or of glioma from reactive gliosis \[[@b3], [@b4]\]. Furthermore, IDH mutations confer a favorable survival prognosis and appear relevant as stratification factor in clinical trials on glioma \[[@b5]\]. Assessment of the IDH status may be performed by DNA-based methods or by immunohistochemical detection of the mutated protein \[[@b6], [@b7], [@b8]\]. A recent study assessed the reliability of these IDH test methods on routine formalin-fixed and paraffin-embedded tumor tissue samples in an interlaboratory ring trial involving 6 international neuropathology laboratories \[[@b9]\]. Immunohistochemistry was found to be highly reproducible despite the fact that the staining protocols varied between the laboratories. In contrast, IDH sequencing procedures yielded discordant results in 2 of 6 laboratories. These results support a previously proposed algorithm for IDH testing based on initial anti-IDH1-R132H immunohistochemistry and subsequent gene sequencing in cases with negative or inconclusive immunostaining results \[[@b7]\]. Importantly, gene sequencing procedures need to be strictly quality controlled.
